CN117925874B - 检测尿路感染病原微生物、耐药基因的引物探针组合及试剂盒 - Google Patents
检测尿路感染病原微生物、耐药基因的引物探针组合及试剂盒 Download PDFInfo
- Publication number
- CN117925874B CN117925874B CN202410328530.2A CN202410328530A CN117925874B CN 117925874 B CN117925874 B CN 117925874B CN 202410328530 A CN202410328530 A CN 202410328530A CN 117925874 B CN117925874 B CN 117925874B
- Authority
- CN
- China
- Prior art keywords
- seq
- detection
- primer
- detection primer
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000523 sample Substances 0.000 title claims abstract description 113
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 82
- 244000000010 microbial pathogen Species 0.000 title claims abstract description 51
- 206010059866 Drug resistance Diseases 0.000 title claims abstract description 31
- 208000019206 urinary tract infection Diseases 0.000 title claims abstract description 29
- 238000001514 detection method Methods 0.000 claims abstract description 180
- 229940079593 drug Drugs 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 35
- 241000588724 Escherichia coli Species 0.000 claims abstract description 14
- 241000588747 Klebsiella pneumoniae Species 0.000 claims abstract description 14
- 241000194031 Enterococcus faecium Species 0.000 claims abstract description 12
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 12
- 241000588626 Acinetobacter baumannii Species 0.000 claims abstract description 11
- 241000222122 Candida albicans Species 0.000 claims abstract description 11
- 241000588697 Enterobacter cloacae Species 0.000 claims abstract description 11
- 241000588770 Proteus mirabilis Species 0.000 claims abstract description 11
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 11
- 229940095731 candida albicans Drugs 0.000 claims abstract description 11
- 101150114434 vanA gene Proteins 0.000 claims abstract description 9
- 241000193985 Streptococcus agalactiae Species 0.000 claims abstract description 8
- 108010002829 beta-lactamase TEM-3 Proteins 0.000 claims abstract description 8
- 101150037181 vanB gene Proteins 0.000 claims abstract description 8
- 210000002700 urine Anatomy 0.000 claims description 15
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 241000194032 Enterococcus faecalis Species 0.000 claims description 8
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 6
- 238000010791 quenching Methods 0.000 claims description 6
- 230000000171 quenching effect Effects 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 108010006785 Taq Polymerase Proteins 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 3
- 108091060592 XDNA Proteins 0.000 claims description 2
- 238000011880 melting curve analysis Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 abstract description 22
- 230000008018 melting Effects 0.000 abstract description 22
- 230000035945 sensitivity Effects 0.000 abstract description 10
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 108091006146 Channels Proteins 0.000 description 12
- 244000005700 microbiome Species 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 238000012795 verification Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 244000052616 bacterial pathogen Species 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000001635 urinary tract Anatomy 0.000 description 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 101710116957 D-alanyl-D-alanine carboxypeptidase Proteins 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 229940041011 carbapenems Drugs 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- 238000012257 pre-denaturation Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002132 β-lactam antibiotic Substances 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- LVFGWOQWXQLVRO-XJDKXYGGSA-N (6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;[(2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound NC(=O)[C@@H]1CC[C@H]2N(OS(O)(=O)=O)C(=O)N1C2.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 LVFGWOQWXQLVRO-XJDKXYGGSA-N 0.000 description 1
- 108010056874 AmpC beta-lactamases Proteins 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 101000735344 Lymantria dispar Pheromone-binding protein 2 Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 102000017033 Porins Human genes 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 229960002379 avibactam Drugs 0.000 description 1
- NDCUAPJVLWFHHB-UHNVWZDZSA-N avibactam Chemical compound C1N2[C@H](C(N)=O)CC[C@@]1([H])N(OS(O)(=O)=O)C2=O NDCUAPJVLWFHHB-UHNVWZDZSA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 101150049515 bla gene Proteins 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940041010 fourth-generation cephalosporins Drugs 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 231100001039 immunological change Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 101150008979 mecA gene Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 101150110399 shv gene Proteins 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/22—Klebsiella
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/37—Proteus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/38—Pseudomonas
- C12R2001/385—Pseudomonas aeruginosa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/44—Staphylococcus
- C12R2001/445—Staphylococcus aureus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/72—Candida
- C12R2001/725—Candida albicans
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种检测尿路感染病原微生物、耐药基因的引物探针组合及试剂盒,病原微生物包括大肠埃希菌、肺炎克雷伯菌、铜绿假单胞菌、奇异变形杆菌、阴沟肠杆菌、鲍曼不动杆菌、屎肠球菌、粪肠球菌、无乳链球菌、金黄色葡萄球菌和白色假丝酵母菌;耐药基因包括CTX‑M‑1、CTX‑M‑9、SHV、TEM、CMY‑2、KPC、NDM、VIM、IMP、OXA‑48、OXA‑23、vanA、vanB、mecA和mecC;上述引物探针序列如SEQ ID NO:1~78所示,探针用于熔解曲线分型。本发明的引物探针具有高特异性和灵敏度、耗时短、检测位点覆盖全面等优点,可为临床医生提供辅助诊断参考,提早进行治疗,临床应用广泛。
Description
技术领域
本发明涉及病原微生物和耐药基因检测技术领域,具体涉及用于检测尿路感染病原微生物、耐药基因的引物探针组合及试剂盒。
背景技术
尿路感染(urinary tract infection, UTI)是社区与医院最常见的感染性疾病之一。由尿路病原菌入侵尿道导致的尿路感染波及了全球超过1.5亿次人口,其复发率之高和日趋加重的抗菌药物耐药正成为社会公共卫生的负担之一。由于女性的尿道短宽直,会阴部和肛门靠近尿道口,细菌更容易上升到女性膀胱;阴道细菌定植频繁,并且因脱垂、尿潴留等因素进而干扰尿液流动和膀胱排空;由于解剖结构和激素水平的变化,妊娠女性更易罹患尿路感染,这些可能是导致女性尿路感染风险增加相关的诱因之一。此外,65岁以上女性由于整个生命周期中生理、激素和免疫变化等原因,尿路感染的几率会随着年龄的增长而增加。
我国女性尿路感染的病原菌以革兰氏阴性杆菌为主,首位是大肠埃希菌是首位的病原菌,其次是革兰阳性球菌、克雷伯菌及假单胞菌属,后者在妊娠期和绝经后的女性尿路感染尤为常见。感染病原菌多为单一菌种,但在复杂性尿路感染中可见两种以上细菌(中国女性尿路感染诊疗专家共识[J].中华医学杂志,2017,97 (36): 2827-2832.)。我国临床尿路感染的诊断金标准为清洁中段尿液细菌培养鉴定及药敏分析,鉴于培养鉴定流程整体耗时较长(约3-5天),因此临床医生在获得药敏试验结果前通常经验性采用抗菌治疗。由于临床上抗生素的广泛应用,如氨基糖苷类、青霉素类、头孢菌素类、碳青霉烯类等,导致尿路感染的病原微生物的分布和发生变化,并诱导耐药性的产生。目前尿路感染常见细菌对抗生素的耐药问题在人群中已经相当普遍,如产超广谱β-内酰胺酶(ESBLs)大肠埃希菌、肺炎克雷伯菌和耐万古霉素肠球菌比例增多。因此快速准确获得病原微生物种类及耐药结果能够帮助临床医生迅速选择治疗方案,提升疗效并减轻病人的痛苦。
目前,常用的针对尿路感染病原微生物核酸和耐药基因的检测方法主要是全自动微生物鉴定及药敏鉴定仪或核酸检测技术。自动鉴定仪检测菌种范围广、操作简便,但需要分离培养出病原微生物纯单菌落才可上机检测,而这使得实验室快速检测病原微生物及明确耐药性这一目标难以实现。核酸检测技术主要分为高通量测序技术和荧光PCR法。在目前公开的检测尿路感染病原微生物核酸和耐药基因文献中,高通量测序技操作繁琐、检测成本高,且对操作技术有较高要求;而荧光PCR法是目前核酸检测技术市场中最为成熟、占有率最高的检测手段,由于其灵敏度高、特异性好、成本可控的特点,在病原微生物检测领域得到广泛应用。但目前荧光PCR法能检测到的病原菌种类和耐药基因较少,且一管检测的病原菌种类和耐药基因有限,无法进行广泛的病原菌和耐药基因筛查。
综上,为了能够快速且全面的检测患者泌尿系统的感染病原微生物及其耐药性,更好指导临床合理用药,急需迫切开发一款覆盖面广泛的新技术。
发明内容
本发明的目的是针对现有技术中对尿路感染病原微生物、耐药基因检测覆盖面窄的问题,提供检测尿路感染病原微生物、耐药基因的引物探针组合及试剂盒,能同时准确区分多种尿路感染病原微生物、耐药基因,只需常规荧光定量PCR仪即可完成检测,检测覆盖面宽、检测成本低、灵敏度好。
本发明技术方案详述如下:
第一方面,本发明提供了检测尿路感染病原微生物、耐药基因的引物探针组合,所述病原微生物包括大肠埃希菌(EC)、肺炎克雷伯菌(KPN)、铜绿假单胞菌(PA)、奇异变形杆菌(PM)、阴沟肠杆菌(ECC)、鲍曼不动杆菌(AB)、屎肠球菌(EFM)、粪肠球菌(EFS)、无乳链球菌(GBS)、金黄色葡萄球菌(SA)和白色假丝酵母菌(CA),检测引物和探针的核苷酸序列如SEQ ID NO:1~33所示;
其中,所述探针的核苷酸序列5’端标记荧光基团,3’端标记淬灭基团;
上述至少6种病原微生物的检测引物和探针能置于一管中供样本检测,可以检测至少一种病原微生物,也可同时用于上述所有病原微生物的检测。一管中同一Tm值范围内不同病原微生物检测探针标记的荧光基团不同。
可选或优选的,所述耐药基因包括CTX-M-1、CTX-M-9、SHV、TEM、CMY-2、KPC、NDM、VIM、IMP、OXA-48、OXA-23、vanA、vanB、mecA和mecC,检测引物和探针的核苷酸序列如SEQ IDNO:34~78所示;
其中,所述探针的核苷酸序列5’端标记荧光基团,3’端标记淬灭基团;
上述至少6种耐药基因的检测引物和探针能置于一管中供样本检测,可以检测至少一种耐药基因,也可同时用于上述所有耐药基因的检测。一管中同一Tm值范围内不同耐药基因检测探针标记的荧光基团不同。
可选或优选的,还包括内参基因GAPDH的检测引物和探针,核苷酸序列如SEQ IDNO: 79~81所示;
GAPDH检测探针的5’端标记荧光基团,3’端标记淬灭基团。
第二方面,本发明提供了检测尿路感染病原微生物、耐药基因的试剂盒,其含有以上任一所述检测尿路感染病原微生物、耐药基因的引物探针组合。
可选或优选的,所述病原微生物检测引物探针组合置于一管内,耐药基因检测引物探针组合置于另一管内。
可选或优选的,还包括PCR反应液,所述PCR反应液每一人份由浓度1U/μL多重扩增的Taq DNA聚合酶0.5~1 μL、浓度10 mM的dNTPs 1~5 μL、浓度5 mM 的Mg2+2~5μL、10×DNA聚合酶buffer 2.5 μL和纯化水补足15 μL组成。
可选或优选的,还包括尿液粗提液,所述尿液粗提液每一人份由50mM Tris HClpH 8.0,体积分数1%的Triton X-100,2mM EDTA,50mM NaOH,体积分数10%的甘油和余量的纯化水组成。
本发明中,所述同一Tm值范围,是指不同的病原微生物检测引物Tm值之间有重叠,不同的耐药基因检测引物Tm值之间有重叠。例如,耐药基因mecA和耐药基因OXA-48的检测引物Tm值分别为55.09~57.92、54.26~57.53,二者有重叠部分为55.09~57.53,则二者属于同一Tm值范围,二者对应的检测探针标记的荧光基团应当不同。
与现有技术相比,本发明具有如下有益效果:
1、可大批量高覆盖率检测不同的病原微生物、耐药基因
本发明的检测引物和探针,能够实现一管内批量同时检测至少一种病原微生物、一管内批量同时检测至少一种耐药基因,一管内批量同时至多检测11种病原微生物、一管内批量同时检测至少15种耐药基因。通过在探针序列增加MGB(minor groove binder, 小沟结合物)修饰和锁核酸(Locked Nucleic Acid,LNA)修饰,提高探针Tm值,增加探针与模板杂交的结合效率。
Tm值,Melting temperature,是指引物与模板之间精准互补并且在模板过量的情况下有50%的引物与模板配对,而另外50%的引物处于解离状态时的温度。
高分辨率熔解曲线(high-resolution melting,HRM)分析,是以单核苷酸熔解温度不同为基础,形成不同形态熔解曲线的基因分析。当饱和荧光染料与DNA双链结合时发出荧光,荧光信号在DNA双链上释放时急剧减弱,如果温度升高可使DNA变性,以温度为横坐标对荧光信号进行作图,即可得到熔解曲线。
LNA是一种含有双糖环的核苷酸衍生物,通过2’氧原子和4’碳原子之间的亚甲基桥键,将糖环锁定成为一个双环的分子模式,从而能很好地限制糖环的灵活性。LNA与核酸配对时导致核苷酸的稳定性提高,因为双螺旋结构随着LNA含量的增加导致核苷酸碱基变成α构型,使核酸酶无法识别磷酸二酯键,从而使寡核苷酸的稳定性提升。LNA与DNA配对时,每增加一个 LNA,Tm值会增加3~8℃,使形成的配对产物拥有较高的解链温度。
在检测时,首先利用特异性引物将不同微生物的目标基因进行扩增,但扩增产物如果直接用饱和荧光染料结合,荧光染料会与所有微生物的扩增产物结合,并不能够通过熔解曲线进行区分,因此加入了具有特定Tm值的检测探针,能够对扩增产物进行不同微生物种类的特异性结合,进而可以通过熔解曲线进行区分。
检测探针在熔解曲线生成期间与PCR扩增产物模板杂交及分离时会产生一个特征峰(Tm值,DNA双链解链50%的温度),由于本发明的检测探针在设计上使得Tm值无重叠的不同病原微生物和耐药基因检测探针可以标记相同的荧光基团,只需要将Tm值有重叠的不同病原微生物和耐药基因检测探针标记不同的荧光基团,这样能够实现同一管内大批量检测的目的。进而可以通过探针的Tm值对各病原微生物的靶基因扩增产物进行任意一种或者多种进行检测。不论是感染病原微生物还是耐药基因,均能批量准确检出。
如本发明实施例,在四种荧光通道(FAM、HEX、ROX 、CY5)采用不同的Tm值分布能够同时对多种病原微生物及耐药基因进行分型,能够批量完成多基因位点检测,检测方法操作简单、判读直观、3个小时内出结果,通用的荧光定量PCR仪均能满足检测需求,实验流程操作简便,能够清晰辨别可以给临床治疗提供重要的参考,以免耽误及时治疗,减少复发频率。
2、检测灵敏度和特异性好,增加对模板的捕获效率
本发明在引物探针序列设计时利用锁核酸技术,在提升Tm值的同时,还可以增强对模板序列的捕获效率和PCR扩增体系的灵敏度和特异性,减少检测的误差。尤其对于以尿液作为样本以及免抽提形式,DNA量少,提高灵敏度是至关重要的。本发明的引物序列可以增加在DNA中对模板的捕获效率,能够以少量样本得出准确的检测结果,更适合临床应用。
3、试剂盒中尿液粗提液可加快基因组释放,无需DNA抽提
本发明所提供的试剂盒包含特殊的尿液粗提液,能够对尿液进行样本强裂解,加快基因组的释放,满足后续PCR扩增的需要。这样在检测时可以采用样本免抽提的方式,5分钟就能对样本进行处理,直接可用于后续的PCR-taqman探针熔解曲线实验。
附图说明
图1为实施例中11种病原微生物及内参基因熔解曲线分布图;
图2为实施例中15种耐药基因及内参基因熔解曲线分布图。
具体实施方式
为了使本技术领域的人员更好地理解本申请方案,下面将结合实施例及附图,对本申请进行清楚、完整地描述,显然,所描述的实施例仅仅是本申请一部分的实施例,而不是全部的实施例。基于本申请中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都应当属于本申请保护的范围。
实施例中除特殊说明外,所用仪器和试剂均为本领域常规仪器和试剂。
实例1 病原微生物与耐药基因的引物探针组设计
对大肠埃希菌(EC)、肺炎克雷伯菌(KPN)、铜绿假单胞菌(PA)、奇异变形杆菌(PM)、阴沟肠杆菌(ECC)、鲍曼不动杆菌(AB)、屎肠球菌(EFM)、粪肠球菌(EFS)、无乳链球菌(GBS)、金黄色葡萄球菌(SA)、白色假丝酵母菌(CA)的已知基因序列进行比较分析,获得各自的差异性基因序列,针对差异性基因序列设计检测引物和探针,同时还增加内参基因GAPDH的检测引物和探针。
所设计的引物具体核苷酸序列如下表所示:
表1 各病原微生物的检测引物序列
注:F表示正向检测引物,R表示反向检测引物,G表示内标基因GAPDH检测引物。
表2 各病原微生物的检测探针序列及Tm值
注:序列中“+”表示锁核酸修饰,此处指修饰“+”前的碱基。
表3 各病原微生物引物探针所对应的微生物目标基因和内参基因序列
表1与表2所展示的探针序列已经进行了荧光基团标记和淬灭基团标记,且探针标示具体的Tm值用于熔解曲线。目标基因检测探针用于熔解曲线生成期间与PCR产物模板杂交及分离时会产生一个特征峰(Tm值,DNA双链解链50%的温度),因此可以通过探针的Tm值对不同微生物进行任一一种或者多种检测。
上述探针组包括FAM、HEX、ROX荧光通道,其中FAM荧光通道包含大肠埃希菌(EC)、肺炎克雷伯菌(KPN)、铜绿假单胞菌(PA)、奇异变形杆菌(PM)、内参基因;HEX荧光通道包含阴沟肠杆菌(ECC)、鲍曼不动杆菌(AB)、屎肠球菌(EFM)、粪肠球菌(EFS);ROX荧光通道包含无乳链球菌(GBS)、金黄色葡萄球菌(SA)、白色假丝酵母菌(CA)。上述11种尿路病原微生物检测引物的Tm值分布在55~85℃之间,且相互之间不会形成干扰,可以在不同荧光通道区分11种病原微生物。
对CTX-M-1、CTX-M-9、SHV、TEM、CMY-2、KPC、NDM、VIM、IMP、OXA-48、OXA-23、vanA、vanB、mecA、mecC的已知基因序列进行比较分析,获得各自的差异性基因序列,针对差异性基因序列设计检测引物和探针,同时还增加内参基因GAPDH的检测引物和探针。
表4 各耐药基因的检测引物序列
注:F表示正向检测引物,R表示反向检测引物,G表示内标基因GAPDH检测引物。
表5 各耐药基因的检测探针序列及Tm值
注:序列中“+”表示锁核酸修饰,此处指修饰“+”前的碱基。
表6 各耐药基因引物探针所对应的耐药基因目标基因和内参基因序列
表3与4所展示的探针组包括FAM、HEX、ROX、CY5荧光通道,其中FAM荧光通道包含mecA、KPC、vanA、vanB、内参基因;HEX荧光通道包含OXA-48、VIM、NDM、IMP;ROX荧光通道包含TEM、CMY-2、SHV、mecC;CY5荧光通道包含CTX-M-1、CTX-M-9、OXA-23。上述15种耐药基因检测引物的Tm值分布在55-85℃之间,且相互之间不会形成干扰,可以在不同的荧光通道区分以上15种耐药基因。
利用上述表1与2,4与5所列引物和探针,制备检测试剂盒(PCR扩增体系试剂盒),包括PCR反应液、引物探针混合液、阳性质控品和阴性质控品,成分如下表7所示:
表7 PCR扩增体系试剂盒组成
实例2 实施例1试剂盒检测方法
一、尿液样本前处理
首先配制尿液粗提液,由50mM Tris HCl pH 8.0,体积分数1%的Triton X-100,2mM EDTA,50mM NaOH,体积分数10%的甘油和余量的纯化水组成。取上述尿液样本加入100μL尿液粗提液,于90℃放置5分钟,用于后续PCR扩增模板使用。
二、PCR-taqman探针熔解曲线实验
1、配制PCR反应液和引物探针混合液;
表8 PCR反应液(15 μL/人份)
上述PCR反应体系中,Taq DNA聚合酶对于多重基因引物探针具有强扩增能力,dNTPs、Mg2+、10×DNA聚合酶buffer之间的配比关系同样直接影响到引物探针组合的扩增效率。
表9 管1-病原微生物引物探针混合液(5μL/人份)
表10 管2-耐药基因的引物探针混合液(5μL/人份)
2、加样
向上述配制的体系中分别加入5μL阴、阳性质控品和步骤1中临床样本模板。进行PCR扩增反应。
3、扩增程序如下:
step1:95℃预变性3min;
step2:94℃变性15s,60℃退火延伸45s,40个循环;
step3:25℃,1min;
4、taqman探针熔解曲线条件
step1:95℃预变性3min;
step2:37℃ 3min;
step3:37℃上升到90℃,升温速率为0.1℃/秒(收集荧光);
step4:25℃,1min;
注:信号收集,收集FAM、HEX、ROX、CY5荧光信号。
5、检测结果分析
根据溶解曲线判断实验结果是否有效,参考数据包括Tm值范围及-d(Rn)/dT(熔解峰纵坐标峰值)。对每一种检测微生物类型的Tm值范围及-d(Rn)/dT值,对照阳性样本与阴性样本进行单独分析,单一种类泌尿道微生物或耐药基因的Tm值范围及-d(Rn)/dT值阈值如表11与表12所示,多种泌尿道微生物或耐药基因组合样本曲线如图1与图2所示。
表11 各病原微生物的判读阈值
11种微生物及内参基因熔解曲线分布图见图1。
表12 各耐药基因微生物的判读阈值
15种耐药基因及内参基因熔解曲线分布图见图2。
通过图1和图2可知,本发明的11种病原微生物能够在一管中一次检测出来,15种耐药基因也能在一管中一次检测出来,检测效率高、覆盖面大,检测结果准确。
实施例3试剂盒检测临床样本特异性验证
准备临床样本30例。使用实施例1中所述试剂盒,采用实施例2中所建立的实验方法,对30例临床样本的检测结果进行判读,以此对本试剂盒进行特异性分析评价。
用试剂盒检测检测结果分析,结果均与临床诊断结果一致,表13所示为所有临床样本检测结果,证明本试剂盒检测特异性良好。
表13 30例临床样本检测结果
注:KPC、IMP、VIM、NDM、OXA-48、OXA-23基因是常见的碳青霉烯类药物耐药基因,亚胺培南/美罗培南属于碳青霉烯类药物。CTX-M、TEM、SHV基因是常见的ESBLs类基因型,ESBLs是能水解青霉素类、氧亚氨基头孢菌素(包括第三、四代头孢菌素)及单环酰胺类氨曲南,且能被β-内酰胺酶抑制剂所抑制的一类β-内酰胺酶(基于CRISPR/Cas13a的金黄色葡萄球菌mecA耐药基因检测方法的建立[J] . 微生物学报, 2023, 63(9): 3628-3640.)。CMY是一种质粒介导的C类头孢菌素酶(AmpC),对超广谱的氧亚胺类头孢菌素和丢失外膜孔蛋白的碳青霉烯类具有抗性,携带CMY-2型基因的病原微生物主要体现为头孢他啶/阿维巴坦(CAZ/AVI)的碳青霉烯耐药(Emergence of transferable ceftazidime-avibactamresistance in KPC-producing Klebsiella pneumoniae due to a novel CMY AmpC β-lactamase in China. Clin Microbiol Infect. 2022;28(1):136.e1-136.e6.)。mecA基因为耐甲氧西林葡萄球菌的标志耐药基因,该基因编码的青霉素结合蛋白(penicillin-binding protein, PBP2a)可水解破坏β-内酰胺抗生素,进而产生对β-内酰胺类抗生素(青霉素、甲氧西林和苯唑西林)等耐药(基于CRISPR/Cas13a的金黄色葡萄球菌mecA耐药基因检测方法的建立[J] . 微生物学报, 2023, 63(9): 3628-3640.)。vanA、vanB基因是常见的万古霉素耐药基因,糖肽类抗生素如万古霉素常被用于其他抗生素耐药的感染,在临床治疗中被广泛使用。
实例4 本发明试剂盒检测灵敏性验证
进一步对本发明试剂盒进行灵敏性验证,使用实施例1中所述试剂盒,采用实施例2中所建立的实验方法,重复测定10次,采用实施例2中所示阈值对结果进行判读。
取大肠埃希菌(ATCC 2941)、肺炎克雷伯菌(ATCC 3076)、NDM和KPC样本,稀释至浓度分别为200 copies/μL、100 copies/μL、50 copies/μL、20 copies/μL、10 copies/μL、5copies/μL的DNA样品5μL作模板进行检测。结果表明该病原微生物组合物及检测方法灵敏度高,检测浓度可达10 copies/μL。
实例5 本发明试剂盒重复性验证
(1)批内重复性验证:使用同一时间配制的实施例1所述试剂盒检测阳性参考品样本,每个参考品按照实施例2所述方法重复检测3次,采用实施例2中所示阈值对结果进行判读,结果见表14。结果表明批内精密度变异系数(CV%)小于等于5%。
表14 批内重复性验证
(2)批间重复性验证:使用不同时间配制(3批)的实施例1所述试剂盒检测阳性样本,每个参考品按照实施例2所述方法重复检测3次,采用实施例2中所示阈值对结果进行判读,结果见表15。结果表明批间精密度变异系数(CV%)小于等于5%。
表15 批间重复性验证
实例6 本发明试剂盒检测稳定性验证
本发明检测试剂盒所用试剂均在-20±5℃储存,储存时间为0个月,3个月,6个月,9个月,12个月,14个月时取出,用实施例1所述试剂盒检测阳性样本,结果见表16,不同时间本发明试剂盒均能出曲线,且能观测到峰。从结果可以看出本发明检测试剂盒在-20±5℃至少能保存12个月。
表16 本发明稳定性验证
本文中应用了具体个例对发明构思进行了详细阐述,以上实施例的说明只是用于帮助理解本发明的核心思想。应当指出,对于本技术领域的普通技术人员来说,在不脱离该发明构思的前提下,所做的任何显而易见的修改、等同替换或其他改进,均应包含在本发明的保护范围之内。
Claims (6)
1.检测尿路感染病原微生物、耐药基因的引物探针组合,适用于高分辨率熔解曲线分析,其特征在于,所述病原微生物包括大肠埃希菌、肺炎克雷伯菌、铜绿假单胞菌、奇异变形杆菌、阴沟肠杆菌、鲍曼不动杆菌、屎肠球菌、粪肠球菌、无乳链球菌、金黄色葡萄球菌和白色假丝酵母菌,检测引物和探针的核苷酸序列如下:
大肠埃希菌检测引物EC-F: SEQ ID NO:1,
大肠埃希菌检测引物EC-R: SEQ ID NO:2,
大肠埃希菌检测探针EC-P: SEQ ID NO:3;
肺炎克雷伯菌检测引物KPN-F: SEQ ID NO:4,
肺炎克雷伯菌检测引物KPN-R: SEQ ID NO:5,
肺炎克雷伯菌检测探针KPN-P: SEQ ID NO:6;
铜绿假单胞菌检测引物PA-F: SEQ ID NO:7,
铜绿假单胞菌检测引物PA-R: SEQ ID NO:8,
铜绿假单胞菌检测探针PA-P: SEQ ID NO:9;
奇异变形杆菌检测引物PM-F: SEQ ID NO:10,
奇异变形杆菌检测引物PM-R: SEQ ID NO:11,
奇异变形杆菌检测探针PM-P: SEQ ID NO:12;
阴沟肠杆菌检测引物ECC-F: SEQ ID NO:13,
阴沟肠杆菌检测引物ECC-R: SEQ ID NO:14,
阴沟肠杆菌检测探针ECC-P: SEQ ID NO:15;
鲍曼不动杆菌检测引物AB-F: SEQ ID NO:16,
鲍曼不动杆菌检测引物AB-R: SEQ ID NO:17,
鲍曼不动杆菌检测探针AB-P: SEQ ID NO:18;
屎肠球菌检测引物EFM-F: SEQ ID NO:19,
屎肠球菌检测引物EFM -R: SEQ ID NO:20,
屎肠球菌检测探针EFM-P: SEQ ID NO:21;
粪肠球菌检测引物EFS-F: SEQ ID NO:22,
粪肠球菌检测引物EFS-R: SEQ ID NO:23,
粪肠球菌检测探针EFS-P: SEQ ID NO:24;
无乳链球菌检测引物GBS-F: SEQ ID NO:25,
无乳链球菌检测引物GBS-R: SEQ ID NO:26,
无乳链球菌检测探针GBS-P: SEQ ID NO:27;
金黄色葡萄球菌检测引物SA-F: SEQ ID NO:28,
金黄色葡萄球菌检测引物SA-R: SEQ ID NO:29,
金黄色葡萄球菌检测探针SA-P: SEQ ID NO:30;
白色假丝酵母菌检测引物CA-F: SEQ ID NO:31,
白色假丝酵母菌检测引物CA-R: SEQ ID NO:32,
白色假丝酵母菌检测探针CA-P: SEQ ID NO:33;
其中,所述探针的核苷酸序列5’端标记荧光基团,3’端标记淬灭基团;
上述至少6种病原微生物的检测引物和探针置于一管中供样本检测,一管中同一Tm值范围内不同病原微生物检测探针标记的荧光基团不同;
所述耐药基因包括CTX-M-1、CTX-M-9、SHV、TEM、CMY-2、KPC、NDM、VIM、IMP、OXA-48、OXA-23、vanA、vanB、mecA和mecC,检测引物和探针的核苷酸序列如下:
CTX-M-1检测引物CTX-M-1-F: SEQ ID NO:34,
CTX-M-1检测引物CTX-M-1-R: SEQ ID NO:35,
CTX-M-1检测探针CTX-M-1-P: SEQ ID NO:36;
CTX-M-9检测引物CTX-M-9-F: SEQ ID NO:37,
CTX-M-9检测引物CTX-M-9-R: SEQ ID NO:38,
CTX-M-9检测探针CTX-M-9-P: SEQ ID NO:39;
SHV检测引物SHV-F: SEQ ID NO:40,
SHV检测引物SHV-R: SEQ ID NO:41,
SHV检测探针SHV-P: SEQ ID NO:42;
TEM检测引物TEM-F: SEQ ID NO:43,
TEM检测引物TEM-R: SEQ ID NO:44,
TEM检测探针TEM-P: SEQ ID NO:45;
CMY-2检测引物CMY-2-F: SEQ ID NO:46,
CMY-2检测引物CMY-2-R: SEQ ID NO:47,
CMY-2检测探针CMY-2-P: SEQ ID NO:48;
KPC检测引物KPC-F: SEQ ID NO:49,
KPC检测引物KPC-R: SEQ ID NO:50,
KPC检测探针KPC-P: SEQ ID NO:51;
NDM检测引物NDM-F: SEQ ID NO:52,
NDM检测引物NDM-R: SEQ ID NO:53,
NDM检测探针NDM-P: SEQ ID NO:54;
VIM检测引物VIM-F: SEQ ID NO:55,
VIM检测引物VIM-R: SEQ ID NO:56,
VIM检测探针VIM-P: SEQ ID NO:57;
IMP检测引物IMP-F: SEQ ID NO:58,
IMP检测引物IMP-R: SEQ ID NO:59,
IMP检测探针IMP-P: SEQ ID NO:60;
OXA-48检测引物OXA-48-F: SEQ ID NO:61,
OXA-48检测引物OXA-48-R: SEQ ID NO:62,
OXA-48检测探针OXA-48-P: SEQ ID NO:63;
OXA-23检测引物OXA-23-F: SEQ ID NO:64,
OXA-23检测引物OXA-23-R: SEQ ID NO:65,
OXA-23检测探针OXA-23-P: SEQ ID NO:66;
vanA检测引物vanA-F: SEQ ID NO:67,
vanA检测引物vanA-R: SEQ ID NO:68,
vanA检测探针vanA-P: SEQ ID NO:69;
vanB检测引物vanB-F: SEQ ID NO:70,
vanB检测引物vanB-R: SEQ ID NO:71,
vanB检测探针vanB-P: SEQ ID NO:72;
mecA检测引物mecA-F: SEQ ID NO:73,
mecA检测引物mecA-R: SEQ ID NO:74,
mecA检测探针mecA-P: SEQ ID NO:75;
mecC检测引物mecC-F: SEQ ID NO:76,
mecC检测引物mecC-R: SEQ ID NO:77,
mecC检测探针mecC-P: SEQ ID NO:78;
其中,所述探针的核苷酸序列5’端标记荧光基团,3’端标记淬灭基团;
上述至少6种耐药基因的检测引物和探针能置于一管中供样本检测,一管中同一Tm值范围内不同耐药基因检测探针标记的荧光基团不同。
2.根据权利要求1所述的引物探针组合,其特征在于,还包括内参基因GAPDH的检测引物和探针,核苷酸序列如下:
GAPDH检测引物: SEQ ID NO: 79~80,
GAPDH检测探针:SEQ ID NO: 81;
GAPDH检测探针的5’端标记荧光基团,3’端标记淬灭基团。
3.检测尿路感染病原微生物、耐药基因的试剂盒,其特征在于,含有权利要求1或2所述检测尿路感染病原微生物、耐药基因的引物探针组合。
4.根据权利要求3所述的试剂盒,其特征在于,所述病原微生物检测引物探针组合置于一管内,耐药基因检测引物探针组合置于另一管内。
5.根据权利要求3所述的试剂盒,其特征在于,还包括PCR反应液,所述PCR反应液每一人份由浓度1U/μL多重扩增的Taq DNA聚合酶0.5~1 μL、浓度10 mM的dNTPs 1~5 μL、浓度5mM 的Mg2+ 2~5μL、10×DNA聚合酶buffer 2.5 μL和纯化水补足15 μL组成。
6.根据权利要求3所述的试剂盒,其特征在于,还包括尿液粗提液,所述尿液粗提液每一人份由50mM Tris HCl pH 8.0,体积分数1%的Triton X-100,2mM EDTA,50mM NaOH,体积分数10%的甘油和余量的纯化水组成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410328530.2A CN117925874B (zh) | 2024-03-21 | 2024-03-21 | 检测尿路感染病原微生物、耐药基因的引物探针组合及试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410328530.2A CN117925874B (zh) | 2024-03-21 | 2024-03-21 | 检测尿路感染病原微生物、耐药基因的引物探针组合及试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117925874A CN117925874A (zh) | 2024-04-26 |
CN117925874B true CN117925874B (zh) | 2024-06-18 |
Family
ID=90764965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410328530.2A Active CN117925874B (zh) | 2024-03-21 | 2024-03-21 | 检测尿路感染病原微生物、耐药基因的引物探针组合及试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117925874B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114934127A (zh) * | 2022-05-20 | 2022-08-23 | 江苏宏微特斯医药科技有限公司 | 用PCR扩增产物的熔点Tm值实现单管检测多个病原体的试剂盒 |
CN115992276A (zh) * | 2023-02-17 | 2023-04-21 | 无锡百泰克生物技术有限公司 | 一种用于检测尿路感染病原体及耐药基因的引物和试剂盒及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1953247A1 (en) * | 2007-01-31 | 2008-08-06 | GC Corporation | A method for measuring the number of oral streptococci, and a PCR primers-probe set used for the same |
JP2009222635A (ja) * | 2008-03-18 | 2009-10-01 | Panasonic Corp | 核酸検出方法 |
US9121046B2 (en) * | 2011-11-16 | 2015-09-01 | New England Biolabs, Inc. | Reducing template independent primer extension and threshold time for loop mediated isothermal amplification |
JP2020115793A (ja) * | 2019-01-24 | 2020-08-06 | 国立大学法人東海国立大学機構 | 肺炎桿菌及び近縁菌種の遺伝子型タイピング法及びこれに用いるプライマーセット |
-
2024
- 2024-03-21 CN CN202410328530.2A patent/CN117925874B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114934127A (zh) * | 2022-05-20 | 2022-08-23 | 江苏宏微特斯医药科技有限公司 | 用PCR扩增产物的熔点Tm值实现单管检测多个病原体的试剂盒 |
CN115992276A (zh) * | 2023-02-17 | 2023-04-21 | 无锡百泰克生物技术有限公司 | 一种用于检测尿路感染病原体及耐药基因的引物和试剂盒及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN117925874A (zh) | 2024-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2478020C (en) | Quantitative assay for the simultaneous detection and speciation of bacterial infections | |
JP6054178B2 (ja) | 抗生物質耐性細菌を検出するための方法およびキット | |
CN105121656A (zh) | Pcr反应混合物及使用其的方法 | |
EP2361989A1 (en) | Assays and kits for serotyping Pseudomonas aeruginosa and oligonucleotide sequences useful in such methods and kits | |
CN102603875B (zh) | 鲍曼复合醋酸钙不动杆菌oxa-23 突变基因的荧光定量pcr 试剂盒 | |
US9388474B2 (en) | Method for detecting toxin-producing Clostridium difficile | |
JP5156726B2 (ja) | ハイブリダイゼーションアッセイを使用する真正細菌群の検出、同定および区別 | |
CN114457174B (zh) | 一种检测尿道病原体感染的多重荧光定量探针法pcr试剂盒 | |
CN113046453A (zh) | 一种基于锁式探针介导的茎环连接的扩增技术检测dna点突变的方法及试剂盒 | |
KR101775406B1 (ko) | 그람음성균 및 항생제 내성에 관련된 유전자들의 동시 검출을 위한 방법 및 그 조성물 | |
US6355435B1 (en) | Methods for detecting and enumerating Campylobacter jejuni in environmental samples and for identifying antibiotic-resistant strains | |
CN117925874B (zh) | 检测尿路感染病原微生物、耐药基因的引物探针组合及试剂盒 | |
CN109457020B (zh) | 耐药性检测组合物、耐药性检测试剂盒及耐药性检测方法 | |
Sanchez-Vega et al. | Quantification of bcl-2/JH fusion sequences and a control gene by multiplex real-time PCR coupled with automated amplicon sizing by capillary electrophoresis | |
EP1567676B1 (en) | Detection, identification and differentiation of eubacterial taxa using a hybridization assay | |
KR102463622B1 (ko) | 패혈증 관련 항생제 내성균 검출용 조성물 및 이의 용도 | |
CN116716422A (zh) | 检测肺炎克雷伯菌k1基因和k2基因的引物、探针、试剂盒及方法 | |
CN116144805A (zh) | 一种耐甲氧西林金黄色葡萄球菌核酸检测试剂盒 | |
CN118600058A (zh) | 引物探针组合、试剂盒及其应用 | |
CN114921574A (zh) | 一种检测碳青霉烯酶编码基因的引物探针组合及其应用 | |
WO2024053642A1 (ja) | フソバクテリウム・ヌクレアタムの検出方法及びフソバクテリウム・ヌクレアタム亜種ヌクレアタムの検出方法 | |
CN117512157A (zh) | 用于变形杆菌多重数字pcr检测的引物探针组合及其试剂盒与应用 | |
WO2001018017A1 (en) | Methods for detecting and enumerating campylobacter jejuni in environmental samples and for identifying antibiotic-resistant strains | |
CN116397037A (zh) | 可视化检测嗜麦芽窄食单胞菌的rpa-lfs引物探针组合及其应用 | |
WO2020167272A2 (en) | Direct carbapenemases triple (kpc-2, oxa-48, ndm-1) pcr diagnostic kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |